<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.111045</article-id><article-id pub-id-type="publisher-id">ACM-40014</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210100000_97466787.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  亚临床甲状腺功能减退对助孕技术临床结局影响的分层分析
  Stratified Analysis of the Effects of Subclinical Hypothyroidism on the Clinical Outcomes of Assisted Pregnancy Techniques
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>佳烨</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>侯</surname><given-names>长江</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>周</surname><given-names>鑫</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>汤</surname><given-names>秀明</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>丁</surname><given-names>钰</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>建新</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff4"><addr-line>青岛市市立医院，山东 青岛</addr-line></aff><aff id="aff3"><addr-line>青岛大学附属医院生殖医学科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><aff id="aff2"><addr-line>青岛大学，山东 青岛</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>01</month><year>2021</year></pub-date><volume>11</volume><issue>01</issue><fpage>312</fpage><lpage>318</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨亚临床甲状腺功能减退(SCH)对体外受精/卵胞浆内单精子显微注射–胚胎移植(IVF/ICSI-ET)助孕患者妊娠结局的影响。方法：回顾性分析2017年1月至2019年11月在青岛大学附属医院生殖医学中心接受IVF/ICSI-ET治疗患者的资料，按促甲状腺激素(TSH)水平分组，分析亚临床甲状腺功能减退对妊娠结局的影响。结果：本研究共纳入了1087例研究对象，结果显示：1) 不同组患者的获卵总数、正常受精率、可移植胚胎数、优质胚胎率、临床妊娠率、流产率及活产率，均无统计学差异(P &gt; 0.05)，但伴随TSH升高存在优质胚胎率下降的趋势；2) 组间生化妊娠率有显著性差异(P &lt; 0.05)，3.8 &lt; TSH ≤ 4.5组生化妊娠率明显增高。结论：亚临床甲减患者行IVF/ICSI-ET治疗发生生化妊娠率、流产率明显增高，优质胚胎率呈下降趋势。因此需对亚临床甲减患者IVF/ICSI-ET治疗过程及孕期甲状腺功能进无行严密监测，预防不良妊娠结局的发生。
    Objective: To investigate the effects of subclinical hypothyroidism (SCH) on the clinical outcomes during in vitro fertilization and embryo transfer (IVF/ICSI-ET). Method: The data of patients undergoing IVF/ICSI-ET from January 2017 to November 2019 in the Reproductive Medical Center of the Affiliated Hospital of Qingdao University were analyzed retrospectively. The influence of subclinical hypothyroidism (SCH) on the clinical outcomes was analyzed. Result: 1087 subjects were enrolled in the study. 1) The number of retrieved oocytes, the fertilization rate, high quality embryo rate, the quality of transplantable embryo, the clinical pregnancy rate, the miscarriage rate, and the live birth rate were not significantly different (P &gt; 0.05). But high quality embryo rate reduces as the TSH rises. 2) Biochemical pregnancy rate has a significant statistical difference, and the biochemical pregnancy rate is significantly higher in the 3.8 &lt; TSH ≤ 4.5 group. Conclusion: The biochemical pregnancy rate and miscarriage rate are significantly higher in SCH patients undergoing IVF/ICSI-ET. And high quality embryo rate showed a downward trend. Therefore, it is necessary to pay more attention to the process of IVF/ICSI-ET and thyroid function during pregnancy of patients with subclinical hypothyroidism to prevent the occurrence of adverse pregnancy outcomes. 
  
 
</p></abstract><kwd-group><kwd>亚临床甲状腺功能减退，促甲状腺激素，体外受精–胚胎移植，妊娠结局, Thyroid Stimulating Hormone (TSH)</kwd><kwd> Subclinical Hypothyroidism (SCH)</kwd><kwd> In Vitro Fertilization/Intracytoplasmic Sperm Injection and Embryo Transfer (IVF/ICSI-ET)</kwd><kwd> Pregnancy Outcomes</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨亚临床甲状腺功能减退(SCH)对体外受精/卵胞浆内单精子显微注射–胚胎移植(IVF/ICSI-ET)助孕患者妊娠结局的影响。方法：回顾性分析2017年1月至2019年11月在青岛大学附属医院生殖医学中心接受IVF/ICSI-ET治疗患者的资料，按促甲状腺激素(TSH)水平分组，分析亚临床甲状腺功能减退对妊娠结局的影响。结果：本研究共纳入了1087例研究对象，结果显示：1) 不同组患者的获卵总数、正常受精率、可移植胚胎数、优质胚胎率、临床妊娠率、流产率及活产率，均无统计学差异(P &gt; 0.05)，但伴随TSH升高存在优质胚胎率下降的趋势；2) 组间生化妊娠率有显著性差异(P &lt; 0.05)，3.8 &lt; TSH ≤ 4.5组生化妊娠率明显增高。结论：亚临床甲减患者行IVF/ICSI-ET治疗发生生化妊娠率、流产率明显增高，优质胚胎率呈下降趋势。因此需对亚临床甲减患者IVF/ICSI-ET治疗过程及孕期甲状腺功能进无行严密监测，预防不良妊娠结局的发生。</p></sec><sec id="s2"><title>关键词</title><p>亚临床甲状腺功能减退，促甲状腺激素，体外受精–胚胎移植，妊娠结局</p></sec><sec id="s3"><title>Stratified Analysis of the Effects of Subclinical Hypothyroidism on the Clinical Outcomes of Assisted Pregnancy Techniques</title><p>Jiaye Zhang<sup>1</sup>, Changjiang Hou<sup>2</sup>, Xin Zhou<sup>3</sup>, Xiuming Tang<sup>2</sup>, Yu Ding<sup>2</sup>, Jianxin Liu<sup>2*</sup></p><p><sup>1</sup>Qingdao University, Qingdao Shandong</p><p><sup>2</sup>Department of Reproductive Medicine, The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><sup>3</sup>Qingdao Municipal Hospital, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/45-1571849x5_hanspub.png" /></p><p>Received: Dec. 25<sup>th</sup>, 2020; accepted: Jan. 19<sup>th</sup>, 2021; published: Jan. 27<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/45-1571849x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To investigate the effects of subclinical hypothyroidism (SCH) on the clinical outcomes during in vitro fertilization and embryo transfer (IVF/ICSI-ET). Method: The data of patients undergoing IVF/ICSI-ET from January 2017 to November 2019 in the Reproductive Medical Center of the Affiliated Hospital of Qingdao University were analyzed retrospectively. The influence of subclinical hypothyroidism (SCH) on the clinical outcomes was analyzed. Result: 1087 subjects were enrolled in the study. 1) The number of retrieved oocytes, the fertilization rate, high quality embryo rate, the quality of transplantable embryo, the clinical pregnancy rate, the miscarriage rate, and the live birth rate were not significantly different (P &gt; 0.05). But high quality embryo rate reduces as the TSH rises. 2) Biochemical pregnancy rate has a significant statistical difference, and the biochemical pregnancy rate is significantly higher in the 3.8 &lt; TSH ≤ 4.5 group. Conclusion: The biochemical pregnancy rate and miscarriage rate are significantly higher in SCH patients undergoing IVF/ICSI-ET. And high quality embryo rate showed a downward trend. Therefore, it is necessary to pay more attention to the process of IVF/ICSI-ET and thyroid function during pregnancy of patients with subclinical hypothyroidism to prevent the occurrence of adverse pregnancy outcomes.</p><p>Keywords:Thyroid Stimulating Hormone (TSH), Subclinical Hypothyroidism (SCH), In Vitro Fertilization/Intracytoplasmic Sperm Injection and Embryo Transfer (IVF/ICSI-ET), Pregnancy Outcomes</p><disp-formula id="hanspub.40014-formula30"><graphic xlink:href="//html.hanspub.org/file/45-1571849x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/45-1571849x8_hanspub.png" /> <img src="//html.hanspub.org/file/45-1571849x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>亚临床甲状腺功能减退，简称亚临床甲减(Subclinical hypothyroidism, SCH)已成为临床常见疾病之一，SCH的患病率在普通人群中为4%~8% [<xref ref-type="bibr" rid="hanspub.40014-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.40014-ref2">2</xref>]，这一比例在育龄期女性人群中更高。甲减典型症状为疲倦、注意力不集中，而SCH患者患往往表现为无症状或仅有边缘性症状，但会对女性月经、生育力有不良影响 [<xref ref-type="bibr" rid="hanspub.40014-ref3">3</xref>]，如增加流产、早产、死胎以及产后子女智力障碍的发生率 [<xref ref-type="bibr" rid="hanspub.40014-ref4">4</xref>]。因此，有必要对行辅助生殖技术(Assisted reproduction technology, ART)的患者的甲状腺功能进行全面评价并建立相应的标准。</p><p>由于SCH患者诊断主要依靠促甲状腺激素(Thyroid stimulating hormone, TSH)，TSH目前被证实为检测轻微程度原发性甲状腺功能异常最灵敏的方法 [<xref ref-type="bibr" rid="hanspub.40014-ref5">5</xref>]。经典的SCH仍定义为血清TSH水平超过4.5 mIU/L，血清游离甲状腺素(FT3, FT4)水平正常 [<xref ref-type="bibr" rid="hanspub.40014-ref4">4</xref>]，但是其诊断标准一直存在争议，尤其是在不孕不育患者人群中。2017年美国甲状腺协会(ATA) [<xref ref-type="bibr" rid="hanspub.40014-ref6">6</xref>] 及2019年我国中华医学会生殖医学会推出的指南 [<xref ref-type="bibr" rid="hanspub.40014-ref7">7</xref>] 均建议，为减少甲状腺疾病的过度治疗，在没有建立特定育龄期妇女TSH参考范围的情况下，将TSH的参考上限由原来的2.5 mU/L提高至4.0~4.5 mU/L。但TSH水平在2.5~4.0 mU/L这一正常范围对不孕患者行体外受精/卵胞浆内单精子显微注射–胚胎移植(In vitro fertilization/ intracytoplasmic sperm injection and embryo transfer, IVF/ICSI-ET)的妊娠结局的影响尚缺乏定论。</p><p>本研究按TSH水平进行细致分组，对在本中心接受IVF/ICSI-ET治疗的不孕患者的TSH水平与妊娠结局的相关性进行了回顾性分析，为SCH的合理诊断及临床治疗提供依据。</p></sec><sec id="s6"><title>2. 材料与方法</title><sec id="s6_1"><title>2.1. 研究对象</title><p>选取2017年1月至2019年11月于我院生殖中心首次接受IVF/ICSI-ET助孕治疗的1087例患者的临床资料，进行回顾性分析。纳入标准：1) 第1次行IVF/ICSI-ET治疗的鲜胚移植周期患者；2) 应用拮抗剂方案超促排卵；3) 既往无甲状腺病史，甲状腺功能检查结果尚未超过1年；4) 双方染色体正常；5) 卵巢储备功能评估正常；6) 有明确的妊娠结局数据。排除标准：1) 6个月内服用任何激素类药物，包括优甲乐(L-T4)；2) 患有肝肾功能不全、心功能不全等其他严重全身疾病；3) 子宫畸形。</p></sec><sec id="s6_2"><title>2.2. 研究方法</title><p>本研究中的患者均于本中心采用拮抗剂方案行超促排卵(controlled ovarian hyperstimulation, COH)，定期行阴道超声和血清性激素水平监测卵泡发育和子宫内膜发育程度。当2个优势卵泡直径达到18 mm及以上或3个优势卵泡达17 mm及以上时，给予人绒毛膜促性腺激素(human chorionic gonadotropin，HCG，珠海丽珠制药) 4000~10,000 U扳机注射，36小时后取卵，后行IVF/ICSI-ET。术后常规给予黄体支持治疗。移植后14天测定血β-HCG，β-HCG阳性但随即转阴者为生化妊娠；β-HCG浓度翻倍正常者于移植后28天行阴道超声检查，有宫内孕囊者为临床妊娠；持续监测孕囊及胚芽生长，心管搏动存在者为持续妊娠。黄体支持采用逐步减量法，于妊娠12周停止黄体支持，胚胎移植后妊娠患者均随访至有明确的妊娠结局。研究方案已得到青岛大学附属医院伦理委员会的同意批准。</p></sec><sec id="s6_3"><title>2.3. 研究分组</title><p>参考既往的研究经验和SCH专家共识 [<xref ref-type="bibr" rid="hanspub.40014-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.40014-ref6">6</xref>]，将TSH正常参考范围0.3~4.5 mIU/L均分为6个区间，期间的5个界值分别为1.0 mIU/L、1.7 mIU/L、2.4 mIU/L、3.1 mIU/L、3.8 mIU/L，将患者行IVF/ICSI-ET治疗前1年内的TSH水平分别按不同界值分组。其中0.3 mIU/L &lt; TSH ≤ 1.0 mIU/L组纳入129例，其中1.0 mIU/L &lt; TSH ≤ 1.7 mIU/L组纳入407例，其中1.7 mIU/L &lt; TSH ≤ 2.4 mIU/L组纳入294例，其中2.4 mIU/L &lt; TSH ≤ 3.1 mIU/L组纳入170例其中3.1 mIU/L &lt; TSH ≤ 3.8 mIU/L组纳入60例，其中3.8 mIU/L &lt; TSH ≤ 4.5 mIU/L组纳入27例。</p></sec><sec id="s6_4"><title>2.4. 检测指标</title><sec id="s6_4_1"><title>2.4.1. 实验室指标</title><p>1) 获卵数：获取的全部卵子数；2) 正常受精率：2原核(2PN)胚胎数/获卵数 &#215; 100%；3) 可移植胚胎数；4) 优质胚胎率(优质胚胎数/2PN胚胎数 &#215; 100%)等。</p></sec><sec id="s6_4_2"><title>2.4.2. 临床指标</title><p>1) 生化妊娠率(生化妊娠周期数/移植周期100%)；2) 临床妊娠率(临床妊娠周期数/移植周期数 &#215; 100%)；3) 流产率(流产周期数/临床妊娠周期数 &#215; 100%)；4) 活产率(分娩活婴的周期数/移植周期数 &#215; 100%)等。</p></sec></sec><sec id="s6_5"><title>2.5. 研究方法</title><p>采用SPSS25.0软件进行统计学分析：符合正态分布的计量资料以均值 &#177; 标准差(x &#177; s)表示；非正态计量资料用中位数M和四分数间距(P25, P75)表示，组间比较选用非参数Kruskal-Wallis H检验。计数资料以百分比(%)表示，组间率的比较采用列联表X2检验或Fisher确切概率法。以P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 基础参数比较</title><p>本研究共纳入1087甲状腺功能正常女性患者，按照TSH进行分组，六组患者在年龄、体重指数(BMI)，基础促卵泡生成素(follicle stimulating hormone, FSH)、窦卵泡数(AFC)对比，均无统计学差异(P &gt; 0.05) (见表1)，六组具有可比性。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of general dat</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >TSH(mIU/L)</th><th align="center" valign="middle" >年龄</th><th align="center" valign="middle" >BMI</th><th align="center" valign="middle" >FSH</th><th align="center" valign="middle" >AFC</th></tr></thead><tr><td align="center" valign="middle" >0.3 &lt; TSH ≤ 1.0</td><td align="center" valign="middle" >34 (30,38)</td><td align="center" valign="middle" >22.20 (20.55,24.80)</td><td align="center" valign="middle" >7.00 (5.58,8.12)</td><td align="center" valign="middle" >11 (8,15)</td></tr><tr><td align="center" valign="middle" >1.0 &lt; TSH ≤ 1.7</td><td align="center" valign="middle" >33 (30,37)</td><td align="center" valign="middle" >22.50 (20.50,25.00)</td><td align="center" valign="middle" >6.89 (5.96,8.32)</td><td align="center" valign="middle" >11 (8.16)</td></tr><tr><td align="center" valign="middle" >1.7 &lt; TSH ≤ 2.4</td><td align="center" valign="middle" >33 (31,36)</td><td align="center" valign="middle" >22.35 (20.57,25.75)</td><td align="center" valign="middle" >6.98 (6.07,8.11)</td><td align="center" valign="middle" >11.5 (9.16)</td></tr><tr><td align="center" valign="middle" >2.4 &lt; TSH ≤ 3.1</td><td align="center" valign="middle" >33 (30,37)</td><td align="center" valign="middle" >22.89 (20.80,25.70)</td><td align="center" valign="middle" >6.87 (9.93,8.32)</td><td align="center" valign="middle" >11 (7,16)</td></tr><tr><td align="center" valign="middle" >3.1 &lt; TSH ≤ 3.8</td><td align="center" valign="middle" >33 (30,36)</td><td align="center" valign="middle" >23.20 (21.11,26.37)</td><td align="center" valign="middle" >6.70 (5.82,8.01)</td><td align="center" valign="middle" >12 (7.25,16)</td></tr><tr><td align="center" valign="middle" >3.8 &lt; TSH ≤ 4.5</td><td align="center" valign="middle" >32 (29,37)</td><td align="center" valign="middle" >22.60 (21.80,24,80)</td><td align="center" valign="middle" >6.18 (5.65,7.28)</td><td align="center" valign="middle" >14 (11,20)</td></tr><tr><td align="center" valign="middle" >H</td><td align="center" valign="middle" >2.98</td><td align="center" valign="middle" >4.402</td><td align="center" valign="middle" >5.588</td><td align="center" valign="middle" >6.204</td></tr><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle" >0.703</td><td align="center" valign="middle" >0.493</td><td align="center" valign="middle" >0.348</td><td align="center" valign="middle" >0.287</td></tr></tbody></table></table-wrap><p>表1. 一般资料比较[M (P25, P75)]</p></sec><sec id="s7_2"><title>3.2. 实验室及妊娠结局相关参数比较</title><p>比较实验室相关参数，如获卵总数、正常受精率、可移植胚胎数、优质胚胎率均无统计学差异(P &lt; 0.05) (见表2)。数据显示虽然差异无统计学差异，但是随着TSH升高，优质胚胎率呈下降趋势，六组的优质胚胎率分别为71.85%、70.76%、69.17%、68.86%、67.76%、66.85%，而与获卵总数、正常受精率、可移植胚胎数无明显相关性。</p><p>比较妊娠结局相关数据显示临床妊娠率、流产率、活产率均无统计学差异(P &gt; 0.05)；比较六组之间的生化妊娠率，差异有统计学意义(P &lt; 0.05)。其中0.3 &lt; TSH ≤ 1.0组1的生化妊娠率最低，为3.10% (4/129)；3.8 &lt; TSH ≤ 4.5组生化妊娠率最高，为22.22% (6/27)。</p><table-wrap-group id="2"><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of transplant-related parameters and pregnancy outcome</title></caption><table-wrap id="2_1"><table><tbody><thead><tr><th align="center" valign="middle" >TSH (mIU/L)</th><th align="center" valign="middle" >获卵总数</th><th align="center" valign="middle" >正常受精率(%)</th><th align="center" valign="middle" >可移植胚胎数</th><th align="center" valign="middle" >优质胚胎率(%)</th><th align="center" valign="middle" >生化妊娠率(%)</th><th align="center" valign="middle" >临床妊娠率(%)</th><th align="center" valign="middle" >流产率(%)</th><th align="center" valign="middle" >活产率(%)</th></tr></thead><tr><td align="center" valign="middle" >0.3 &lt; TSH ≤ 1.0</td><td align="center" valign="middle" >8 (6,9)</td><td align="center" valign="middle" >74.64</td><td align="center" valign="middle" >4(3,6.5)</td><td align="center" valign="middle" >71.85</td><td align="center" valign="middle" >3.10</td><td align="center" valign="middle" >44.96</td><td align="center" valign="middle" >15.52</td><td align="center" valign="middle" >37.21</td></tr><tr><td align="center" valign="middle" >1.0 &lt; TSH ≤ 1.7</td><td align="center" valign="middle" >8 (5,10)</td><td align="center" valign="middle" >71.82</td><td align="center" valign="middle" >4(3,6)</td><td align="center" valign="middle" >70.76</td><td align="center" valign="middle" >3.93</td><td align="center" valign="middle" >46.19</td><td align="center" valign="middle" >15.43</td><td align="center" valign="middle" >38.08</td></tr><tr><td align="center" valign="middle" >1.7 &lt; TSH ≤ 2.4</td><td align="center" valign="middle" >7 (5,10)</td><td align="center" valign="middle" >71.63</td><td align="center" valign="middle" >4(2,6)</td><td align="center" valign="middle" >69.17</td><td align="center" valign="middle" >4.76</td><td align="center" valign="middle" >55.78</td><td align="center" valign="middle" >25.61</td><td align="center" valign="middle" >40.47</td></tr></tbody></table></table-wrap><table-wrap id="2_2"><table><tbody><thead><tr><th align="center" valign="middle" >2.4 &lt; TSH ≤ 3.1</th><th align="center" valign="middle" >7 (6,9)</th><th align="center" valign="middle" >75.09</th><th align="center" valign="middle" >4(3,6)</th><th align="center" valign="middle" >68.86</th><th align="center" valign="middle" >5.29</th><th align="center" valign="middle" >48.82</th><th align="center" valign="middle" >27.71</th><th align="center" valign="middle" >32.94</th></tr></thead><tr><td align="center" valign="middle" >3.1 &lt; TSH ≤ 3.8</td><td align="center" valign="middle" >7 (6,9)</td><td align="center" valign="middle" >72.21</td><td align="center" valign="middle" >4(3,6)</td><td align="center" valign="middle" >67.76</td><td align="center" valign="middle" >8.33</td><td align="center" valign="middle" >50.00</td><td align="center" valign="middle" >20.00</td><td align="center" valign="middle" >36.67</td></tr><tr><td align="center" valign="middle" >3.8 &lt; TSH ≤ 4.5</td><td align="center" valign="middle" >8 (6,11)</td><td align="center" valign="middle" >74.79</td><td align="center" valign="middle" >6(4,8)</td><td align="center" valign="middle" >66.85</td><td align="center" valign="middle" >22.22</td><td align="center" valign="middle" >48.15</td><td align="center" valign="middle" >23.08</td><td align="center" valign="middle" >37.04</td></tr><tr><td align="center" valign="middle" >H/X2</td><td align="center" valign="middle" >10.377</td><td align="center" valign="middle" >7.730</td><td align="center" valign="middle" >9.49</td><td align="center" valign="middle" >4.178</td><td align="center" valign="middle" >14.188</td><td align="center" valign="middle" >7.529</td><td align="center" valign="middle" >9.099</td><td align="center" valign="middle" >2.674</td></tr><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle" >0.065</td><td align="center" valign="middle" >0.172</td><td align="center" valign="middle" >0.091</td><td align="center" valign="middle" >0.524</td><td align="center" valign="middle" >0.010</td><td align="center" valign="middle" >0.184</td><td align="center" valign="middle" >0.098</td><td align="center" valign="middle" >0.750</td></tr></tbody></table></table-wrap></table-wrap-group><p>表2. 移植相关参数及妊娠结局比较[M (P25, P75), n(%)]</p></sec></sec><sec id="s8"><title>4. 讨论</title><sec id="s8_1"><title>4.1. 甲状腺功能与女性生殖</title><p>甲状腺与女性生殖功能密切相关，其联系主要基于下丘脑–垂体–性腺轴和下丘脑–垂体–甲状腺轴之间的相互影响。在生理条件下，下丘脑产生促性腺激素释放激素(Gonadotropin release hormone, GnRH)，刺激垂体产生促黄体生成素(Luteinizing hormone, LH)和FSH。LH和FSH控制卵巢中雌二醇(E2)和孕激素的产生，另外，LH和FSH也控制抑制素和激活素的产生。另一方面，E2和孕激素在下丘脑和垂体水平调节GnRH、LH和FSH的分泌，称为经典的反馈机制。在下丘脑–垂体–甲状腺轴中，下丘脑分泌促甲状腺素释放激素(Thyrotropin releasing hormone, TRH)，TRH调节TSH的分泌，最后，在TSH的刺激下，甲状腺产生甲状腺激素(thyroid hormone, TH)。TH主要有三碘甲腺原氨酸(T3)和四碘甲腺原氨酸(T4)。T3、T4、TSH与TRH间也存在反馈机制 [<xref ref-type="bibr" rid="hanspub.40014-ref4">4</xref>]。研究证实，TH与其他激素(主要是性激素)之间具有持续相互作用 [<xref ref-type="bibr" rid="hanspub.40014-ref8">8</xref>]。动物实验证明，TH可协同FSH对颗粒细胞的增殖、分化、凋亡等产生直接作用，对卵巢颗粒细胞功能发挥了促进作用 [<xref ref-type="bibr" rid="hanspub.40014-ref9">9</xref>]。此外TH对FSH诱导颗粒细胞表面LH/HCG受体的生成及孕酮的分泌有促进作用。因此，甲状腺功能减退可能通过减弱颗粒细胞对FSH的反应性而使卵泡质量下降 [<xref ref-type="bibr" rid="hanspub.40014-ref1">1</xref>]。</p><p>FSH、LH和TSH均为异源二聚体糖蛋白激素，三者化学结构相似 [<xref ref-type="bibr" rid="hanspub.40014-ref10">10</xref>]，促甲状腺激素受体(Thyroid-stimulating hormone receptors, TSHR)属于G蛋白偶联受体家族。促卵泡生成素受体和促黄体生成素受体也为该家族的密切相关成员，它们拥有共同的a亚基 [<xref ref-type="bibr" rid="hanspub.40014-ref11">11</xref>]，TSH与FSH、LH间可能存在交叉反应 [<xref ref-type="bibr" rid="hanspub.40014-ref12">12</xref>]。另外，TSHR mRNA在卵母细胞、卵巢颗粒细胞、卵巢表面上皮细胞、和子宫内膜细胞上均有表达 [<xref ref-type="bibr" rid="hanspub.40014-ref13">13</xref>]，TSH可以直接作用于卵巢及卵母细胞，影响卵泡的发育、卵巢储备功能及子宫内膜的容受性。</p><p>还有研究显示，甲减患者体内的雌激素及雄激素水平均下降，其原因可能为甲减时雄烯二酮和雌酮的代谢清除率降低，同时，血清性激素结合球蛋白水平及其血浆结合活性降低，导致体内睾酮和E2的水平均下降 [<xref ref-type="bibr" rid="hanspub.40014-ref14">14</xref>]。长期甲减患者体内可能存在慢频率脉冲式分泌GnRH，而GnRH的慢频率脉冲式分泌可以促进FSH的合成与分泌，LH反应延迟、水平相对减低，导致FSH/LH比值升高，提示卵巢储备功能减退 [<xref ref-type="bibr" rid="hanspub.40014-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.40014-ref15">15</xref>]。</p><p>目前尚缺乏TSH升高对子宫内膜损害的直接证据，但TSH可以通过影响内膜厚度、内膜血管生成等方面降低子宫内膜的容受性。研究证实，甲状腺功能的低下会引起LH分泌被抑制，导致排卵障碍 [<xref ref-type="bibr" rid="hanspub.40014-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.40014-ref14">14</xref>]。</p></sec><sec id="s8_2"><title>4.2. COH对甲状腺功能的影响</title><p>本研究结果显示随着TSH逐渐增高，胚胎质量、胚胎着床率逐渐下降，而生化妊娠率逐渐上升，并且差异有统计学意义；优质胚胎率、流产率虽无统计学差异，但是随着TSH逐渐增高，优质胚胎率显著下降，流产率显著上升。与既往的研究结果一致，即TSH和甲状腺功能与IVF妊娠结局相关 [<xref ref-type="bibr" rid="hanspub.40014-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.40014-ref16">16</xref>]。同时，甲状腺功能减低对试管婴儿周期的获卵率、胚胎种植率、临床妊娠率、活产率均有影响。研究表明，ART患者COH后血清TSH水平显著升高，目前已证实，这种变化与COH过程中E2的快速增加有关。甲状腺结合球蛋白(Thyroxine-binding globulin, TBG)由肝脏合成，随着E2的升高，诱导肝细胞合成TBG明显增多，同时E2还可以改变TBG的糖基化反应，使其半衰期延长而清除率减慢，从而进一步增加了血清中TBG的水平 [<xref ref-type="bibr" rid="hanspub.40014-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.40014-ref18">18</xref>]。因为血清中大部分T4和T3与TBG结合，且TBG对T4的亲和力最高，导致游离T4减少，可能加重潜在的SCH。因此，应在COH之前监测甲状腺功能，严格控制TSH，如果血清TSH水平高，则应在开始之前给予药物治疗。另外，有报道称，TSH水平可能为预测ART患者成功率的有效指标，TSH升高预示着ART患者的受精不良 [<xref ref-type="bibr" rid="hanspub.40014-ref1">1</xref>]。</p></sec><sec id="s8_3"><title>4.3. SCH和妊娠</title><p>甲状腺素对于胎盘和胎儿的正常发育至关重要。由于胎儿的甲状腺大约于孕16周时才开始产生大量的TH，因此胎儿在孕早期完全依赖于母体的甲状腺功能以获得TH。在整个妊娠期间，母体游离甲状腺素必须比受孕前水平升高约50%以支持胎儿的需求 [<xref ref-type="bibr" rid="hanspub.40014-ref19">19</xref>]。妊娠初期(孕4~6周)，母体的TH需求显著增加，为了维持TH的稳态，甲状腺必须产生更多的TH，直到妊娠中期达到新的稳态。而TH的生成又取决于碘的补充及良好的甲状腺功能。因此，妊娠可能加重原有的甲状腺疾病，任何甲状腺功能紊乱均可能对妊娠结局产生不良影响 [<xref ref-type="bibr" rid="hanspub.40014-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.40014-ref20">20</xref>]。由于妊娠期甲减对妊娠结局及新生儿均会产生不良影响，应及时在妊娠早期对孕妇进行常规甲状腺筛查，早期诊断有利于积极控制病情，改善妊娠结局。目前临床首选左旋甲状腺素(Levothyroxine, L-T4)治疗妊娠期甲减，它能有效调节TSH水平，达到指南要求的治疗目标，且副反应较小 [<xref ref-type="bibr" rid="hanspub.40014-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.40014-ref21">21</xref>]。有研究显示，妊娠期SCH患者接受甲状腺激素治疗可降低流产、死产风险 [<xref ref-type="bibr" rid="hanspub.40014-ref7">7</xref>]。</p><p>本研究结果显示，血清TSH水平对IVF/ICSI-ET成功率、早期流产率等临床结局产生影响。近期研究表明，SCH对妊娠结局和胎儿健康均可带来不良影响，母体TSH升高会导致早期、晚期产科并发症(即流产、早产、胎盘早剥、胎死宫内、产后出血、新生儿转入重症监护室等)的风险增加 [<xref ref-type="bibr" rid="hanspub.40014-ref8">8</xref>]。必须密切监测甲功异常的ART患者。另一方面，在既往的一项回顾性研究中，对比TSH临界值为2.5 mIU/L或4.5 mIU/L的新鲜周期IVF患者，未观察到临床妊娠率、分娩率或流产率的差异 [<xref ref-type="bibr" rid="hanspub.40014-ref4">4</xref>]。</p><p>我们的研究的局限性在于，研究人群仅限于接收IVF/ICSI-ET治疗的女性人群，患者数量不多，收集的关于潜在混杂变量的数据有限。大多数患者仅获得TSH值，缺少游离T3、T4和甲状腺抗体等相关研究数据。并且，没有随访患者孕期的妊娠并发症及新生儿远期结局，故本研究仍需扩大样本量，必要时进行前瞻性研究证实。</p></sec></sec><sec id="s9"><title>文章引用</title><p>张佳烨,侯长江,周 鑫,汤秀明,丁 钰,刘建新. 亚临床甲状腺功能减退对助孕技术临床结局影响的分层分析Stratified Analysis of the Effects of Subclinical Hypothyroidism on the Clinical Outcomes of Assisted Pregnancy Techniques[J]. 临床医学进展, 2021, 11(01): 312-318. https://doi.org/10.12677/ACM.2021.111045</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.40014-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Kim, C.H., Ahn, J.W., Park, S.J., Kim, S.H., Chae, H.D. and Kang, B.M. (2011) Effect of Levothyroxine Treatment on In Vitro Fertilization and Pregnancy Outcome in Infertile Women with Subclinical Hypothyroidism Undergoing in Vitro Fertilization/Intracytoplasmic Sperm Injection. Fertility &amp; Sterility, 95, 1650-1654. 
&lt;br&gt;https://doi.org/10.1016/j.fertnstert.2010.12.004</mixed-citation></ref><ref id="hanspub.40014-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会生殖医学分会第四届委员会. 不孕女性亚临床甲状腺功能减退诊治的中国专家共识(初稿) [J]. 中华生殖与避孕杂志, 2019, 39(8): 609-621.</mixed-citation></ref><ref id="hanspub.40014-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Vissenberg, R., Manders, V.D., Mastenbroek, S., Fliers, E., Afink, G.B., Ris-Stalpers, C., et al. (2015) Pathophysiological Aspects of Thyroid Hormone Disorders/Thyroid Peroxidase Autoantibodies and Reproduction. Human Reproduction Update, 21, 378-387. &lt;br&gt;https://doi.org/10.1093/humupd/dmv004</mixed-citation></ref><ref id="hanspub.40014-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Dittrich, R., Beckmann, M.W., Oppelt, P.G., Hoffmann, I., Lotz, L., Kuwert, T., et al. (2011) Thyroid Hormone Receptors and Reproduction. Journal of Reproductive Immunology, 90, 58-66.  
&lt;br&gt;https://doi.org/10.1016/j.jri.2011.02.009</mixed-citation></ref><ref id="hanspub.40014-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Benhadi, N., Wiersinga, W.M., Reitsma, J.B., Vrijkotte, T.G.M. and Bonsel, G.J. (2009) Higher Maternal TSH Levels in Pregnancy Are Associated with Increased Risk for Miscarriage, Fetal or Neonatal Death. European Journal of Endocrinology, 160, 985-991. &lt;br&gt;https://doi.org/10.1530/EJE-08-0953</mixed-citation></ref><ref id="hanspub.40014-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Alexander, E.K., Pearce, E.N., Brent, G.A., Brown, R.S., Chen, H., Dosiou, C., et al. (2017) 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease during Pregnancy and the Postpartum. Thyroid, 27, 315-389. &lt;br&gt;https://doi.org/10.1089/thy.2016.0457</mixed-citation></ref><ref id="hanspub.40014-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">《妊娠和产后甲状腺疾病诊治指南》编撰委员会, 中华医学会内分泌学分会, 中华医学会围产医学分会. 妊娠和产后甲状腺疾病诊治指南(第2版) [J]. 中华内分泌代谢杂志, 2019, 35(8): 636-665.</mixed-citation></ref><ref id="hanspub.40014-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Poppe, K., Velkeniers, B. and Glinore, D. (2008) The Role of Thyroid Autoimmunity in Fertility and Pregnancy. Nature Clinical Practice Endocrinology &amp; Metabolism, 4, 394-405. &lt;br&gt;https://doi.org/10.1038/ncpendmet0846</mixed-citation></ref><ref id="hanspub.40014-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Fedail, J.S., Zheng, K., Wei, Q., Kong, L.F. and Shi, F.X. (2014) Roles of Thyroid Hormones in Follicular Development in the Ovary of Neonatal and Immature Rats. Endocrine, 46, 594-604. 
&lt;br&gt;https://doi.org/10.1007/s12020-013-0092-y</mixed-citation></ref><ref id="hanspub.40014-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Wide, L. and Eriksson, K. (2017) Molecular Size and Charge as Dimensions to Identify and Characterize Circulating Glycoforms of Human FSH, LH and TSH. Upsala Journal of Medical Sciences, 122, 217-223. 
&lt;br&gt;https://doi.org/10.1080/03009734.2017.1412373</mixed-citation></ref><ref id="hanspub.40014-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">路瑶, 陈子江. 甲状腺功能对女性生育力的影响[J]. 生殖与避孕, 2015, 35(5): 339-344.</mixed-citation></ref><ref id="hanspub.40014-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Practice Committee of the American Society for Reproductive Medicine (2015) Subclinical Hypothyroidism in the Infertile Female Population: A Guideline. Fertility and Sterility, 104, 545-553.  
&lt;br&gt;https://doi.org/10.1016/j.fertnstert.2015.05.028</mixed-citation></ref><ref id="hanspub.40014-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Aghajanova, L., Lindeberg, M., Carlsson, I.B., Stavreus-Evers, A., Zhang, P., Scott, J.E., et al. (2009) Receptors for Thyroid-Stimulating Hormone and Thyroid Hormones in Human Ovarian Tissue. Reprod Biomed Online, 18, 337-347.  
&lt;br&gt;https://doi.org/10.1016/S1472-6483(10)60091-0</mixed-citation></ref><ref id="hanspub.40014-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Krassas, G.E., Poppe, K. and Glinore, D. (2010) Thyroid Function and Human Reproductive Health. Endocrine Reviews, 31, 702-755. &lt;br&gt;https://doi.org/10.1210/er.2009-0041</mixed-citation></ref><ref id="hanspub.40014-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">谢聪聪, 王雪莹, 姚冠峰, 等. 甲状腺激素在卵泡发生中作用的研究进展[J]. 基础医学与临床, 2019, 39(3): 428-433.</mixed-citation></ref><ref id="hanspub.40014-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Mintziori, G., Goulis, D.G., Glalamas, E., Dosopoulos, K., Zouzoulas, D., Gitas, G., et al. (2014) Association of TSH Concentrations and Thyroid Autoimmunity with IVF Outcome in Women with TSH Concentrations within Normal Adult Range. Gynecologic and Obstetric Investigation, 77, 84-88. &lt;br&gt;https://doi.org/10.1159/000357193</mixed-citation></ref><ref id="hanspub.40014-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">华梦婷. 妊娠期妇女血清甲状腺激素变化的研究[J]. 国际感染病学(电子版), 2019, 8(3): 227-228.</mixed-citation></ref><ref id="hanspub.40014-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Reinblatt, S., Herrero, B., Correa Jose, A., Shalom-Paz, E., Ata, B., Wiser, A., et al. (2013) Thyroid Stimulating Hormone Levels Rise after Assisted Reproductive Technology. Journal of Assisted Reproduction and Genetics, 30, 1347-1352. &lt;br&gt;https://doi.org/10.1007/s10815-013-0081-3</mixed-citation></ref><ref id="hanspub.40014-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Gingold, J.A., Zafman, K., Rodriguez-Purata, J., Whitehouse, M.C., Lee, J.A., Sandler, B., et al. (2016) Do Elevated TSH Levels Predict Early Pregnancy Loss in ART Patients? Gynecological Endocrinology, 32, 973-976. 
&lt;br&gt;https://doi.org/10.1080/09513590.2016.1200553</mixed-citation></ref><ref id="hanspub.40014-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, M., Wang, M., Li, J., Luo, X.H. and Lei, M.X. (2019) Effects of Thyroid Diseases on Pregnancy Outcomes. Experimental and Therapeutic, 18, 1807-1815. &lt;br&gt;https://doi.org/10.3892/etm.2019.7739</mixed-citation></ref><ref id="hanspub.40014-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Velkeniers, B., Van Meerhaeghe, A., Poppe, K., Unuane, D., Tournaye, H. and Haentjens, P. (2013) Levothyroxine Treatment and Pregnancy Outcome in Women with Subclinical Hypothyroidism Undergoing Assisted Reproduction Technologies: Systematic Review and Meta-Analysis of RCTs. Human Reproduction Update, 19, 251-258.  
&lt;br&gt;https://doi.org/10.1093/humupd/dms052</mixed-citation></ref></ref-list></back></article>